

# Henry Leonidas Gomez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8454647/publications.pdf>

Version: 2024-02-01

89  
papers

13,066  
citations

53794

45  
h-index

45317

90  
g-index

91  
all docs

91  
docs citations

91  
times ranked

16345  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 239-246.e4.	2.4	15
2	Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience. <i>PLoS ONE</i> , 2020, 15, e0237811.	2.5	12
3	Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women. <i>Cancer Research</i> , 2020, 80, 1893-1901.	0.9	29
4	Role of undifferentiation markers and androgen receptor expression in triple-negative breast cancer. <i>Breast Journal</i> , 2019, 25, 1316-1319.	1.0	3
5	Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America. <i>Ecancermedicalscience</i> , 2019, 13, 896.	1.1	8
6	Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1127-1134.	2.4	20
7	Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies. <i>Biomarkers in Medicine</i> , 2019, 13, 1481-1491.	1.4	16
8	Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 4899.	3.3	91
9	Breast cancer subtype and survival among Indigenous American women in Peru. <i>PLoS ONE</i> , 2018, 13, e0201287.	2.5	8
10	Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. <i>World Journal of Clinical Oncology</i> , 2018, 9, 33-41.	2.3	23
11	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 649-657.	7.0	108
12	Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. <i>Journal of Surgical Oncology</i> , 2017, 115, 647-662.	1.7	13
13	In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies. <i>Scientific Reports</i> , 2017, 7, 1526.	3.3	60
14	Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. <i>Clinical and Translational Oncology</i> , 2017, 19, 1478-1488.	2.4	46
15	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	7.1	118
16	Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 20282-20292.	1.8	28
17	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 2221-2231.	1.6	148
18	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 507-515.	2.5	27

#	ARTICLE	IF	CITATIONS
19	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	6.3	24
20	A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease. <i>Npj Genomic Medicine</i> , 2016, 1, 15015.	3.8	50
21	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. <i>Science Translational Medicine</i> , 2016, 8, 334ra53.	12.4	105
22	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptorâ€“Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408.	1.6	65
23	A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American) Tj ETQq1 20.7843140gBT /Ove	2.0	14
24	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042.	1.6	315
25	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509.	7.0	428
26	Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. <i>World Journal of Clinical Oncology</i> , 2016, 7, 387.	2.3	42
27	PIK3CA mutated, hormonal receptors and HER2: individual targets but partnered in the escape to targeted therapy in breast cancer. <i>Translational Cancer Research</i> , 2016, 5, S789-S793.	1.0	0
28	Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 392-393.	0.4	1
29	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 923-932.	27.0	452
30	Prognostic factors for patients with newly diagnosed brain metastasis from breast cancer. <i>CNS Oncology</i> , 2015, 4, 137-145.	3.0	8
31	Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	37
32	PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2014, 7, 142-148.	0.9	18
33	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. <i>Cancer Discovery</i> , 2014, 4, 232-245.	9.4	413
34	Advanced Extramammary Paget's Disease of the Groin, Penis, and Scrotum. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S13107.	1.3	27
35	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3â€“98. <i>Psycho-Oncology</i> , 2014, 23, 173-182.	2.3	55
36	Emergence of Constitutively Active Estrogen Receptor-Î± Mutations in Pretreated Advanced Estrogen Receptorâ€“Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1757-1767.	7.0	529

#	ARTICLE	IF	CITATIONS
37	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. <i>Breast Cancer Research</i> , 2014, 16, 406.	5.0	267
38	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	27.0	621
39	A phase 3 trial comparing capecitabine in combination with Sorafenib or placebo for treatment of locally advanced or metastatic HER2-Negative breast Cancer (the RESILIENCE study): study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 228.	1.6	34
40	Planning cancer control in Latin America and the Caribbean. <i>Lancet Oncology</i> , The, 2013, 14, 391-436.	10.7	394
41	Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 346-352.	1.0	7
42	A randomized phase II study of lapatinib+Pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 471-482.	2.5	55
43	A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 755-766.	2.5	42
44	Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6346-6358.	0.9	124
45	Breast Cancer in Young Women in Latin America: An Unmet, Growing Burden. <i>Oncologist</i> , 2013, 18, 1298-1306.	3.7	84
46	Breast Cancer in Young Women in Latin America: An Unmet, Growing Burden. <i>Oncologist</i> , 2013, 18, 26-34.	3.7	33
47	Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3703-3713.	7.0	119
48	Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1947-1953.	1.6	128
49	Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. <i>Haematologica</i> , 2013, 98, 357-363.	3.5	51
50	Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2012, 5, 152-157.	0.9	1
51	Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 335-341.	1.4	36
52	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2012, 379, 633-640.	18.7	1,165
53	Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 696-706.	10.7	109
54	Small-Cell Cancer of the Breast: What Is the Optimal Treatment? A Report and Review of Outcomes. <i>Clinical Breast Cancer</i> , 2012, 12, 287-292.	2.4	22

#	ARTICLE	IF	CITATIONS
55	Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline- and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data From 2 Phase III Randomized Clinical Trials. <i>Clinical Breast Cancer</i> , 2012, 12, 240-246.	2.4	11
56	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <i>Nature Medicine</i> , 2012, 18, 1052-1059.	30.7	219
57	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 333-343.	2.5	106
58	Behaviour of breast cancer molecular subtypes through tumour progression. <i>Clinical and Translational Oncology</i> , 2012, 14, 481-485.	2.4	15
59	A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1049-1056.	2.5	39
60	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.	1.6	190
61	Global experience with ixabepilone in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 683-692.	2.4	3
62	Implication of miRNA in the diagnosis and treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1265-1275.	2.4	20
63	Topoisomerase II- $\alpha$ as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. <i>Breast</i> , 2011, 20, 39-45.	2.2	9
64	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. <i>Journal of Translational Medicine</i> , 2011, 9, 204.	4.4	500
65	BIM Expression in Treatment-Na $\tilde{v}$ e Cancers Predicts Responsiveness to Kinase Inhibitors. <i>Cancer Discovery</i> , 2011, 1, 352-365.	9.4	268
66	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1873.	7.4	531
67	Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 409-418.	2.5	65
68	The phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 751-759.	5.9	146
69	Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database. <i>Clinical Breast Cancer</i> , 2010, 10, 294-300.	2.4	119
70	Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. <i>Clinical Cancer Research</i> , 2010, 16, 2688-2695.	7.0	137
71	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5351-5361.	7.0	185
72	Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2010, 26, 767-775.	1.9	13

#	ARTICLE	IF	CITATIONS
73	Pazopanib: an antiangiogenic drug in perspective. <i>Future Oncology</i> , 2009, 5, 1335-1348.	2.4	22
74	Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5538-5546.	1.6	948
75	Analysis of dermatologic events in patients with cancer treated with lapatinib. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 485-493.	2.5	78
76	Combined lapatinib and paclitaxel in HER2-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 308-309.	27.6	10
77	Prolonged Disease Control in a Patient With Anthracycline- and Taxane-Resistant Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, E1-E3.	2.4	1
78	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009, 374, 1512-1520.	13.7	588
79	PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R27.	5.0	49
80	Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2999-3005.	1.6	321
81	Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib. <i>Journal of Clinical Oncology</i> , 2008, 26, 1253-1259.	1.6	44
82	Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5544-5552.	1.6	407
83	Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. <i>Journal of Clinical Oncology</i> , 2007, 25, 5210-5217.	1.6	465
84	Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. <i>Lancet Oncology, The</i> , 2007, 8, 203-211.	10.7	175
85	Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4236-4244.	1.6	621
86	A Phase II Trial of Pemetrexed in Advanced Breast Cancer: Clinical Response and Association with Molecular Target Expression. <i>Clinical Cancer Research</i> , 2006, 12, 832-838.	7.0	59
87	The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. <i>British Journal of Haematology</i> , 2002, 118, 218-228.	2.5	19
88	A Phase II Study of Neoadjuvant Gemcitabine Plus Doxorubicin in Stage IIIB Breast Cancer: A Preliminary Report. <i>Seminars in Oncology</i> , 2001, 28, 57-61.	2.2	13
89	Ifosfamide plus Cisplatin as Primary Chemotherapy of Advanced Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 67, 168-171.	1.4	11